^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Glutamate inhibitor

    Related drugs:
    3d
    RILUSCI: Riluzole in the Treatment of Spasticity in the Traumatic Chronic Spinal Cord Injury Condition (clinicaltrials.gov)
    P2, N=90, Recruiting, Assistance Publique Hopitaux De Marseille | Not yet recruiting --> Recruiting
    Enrollment open
    |
    riluzole
    19d
    A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients (clinicaltrials.gov)
    P1/2, N=153, Not yet recruiting, PLL TX AUSTRALIA PTY LTD | Trial completion date: Dec 2026 --> Jun 2027
    Trial completion date
    21d
    A Phase 2, Randomized, Double-Blind, Double-Dummy Study Evaluating the Efficacy, Safety and Biomarkers Effect of ILB versus Riluzole in participants with Amyotrophic Lateral Sclerosis (2024-513927-18-00)
    P1/2, N=116, Recruiting, Oslo University Hospital HF | Not yet recruiting --> Recruiting
    Enrollment open
    |
    riluzole
    1m
    Regulation of Autophagy and Metabolism in Hepatocellular Carcinoma: Involvement of Wnt-β-Catenin Pathway. (PubMed, J Cell Mol Med)
    Riluzole disrupts mitochondrial homeostasis by increasing Bax/Bcl-2 ratio, resulting in a drop of mitochondrial membrane potential. In conclusion, riluzole inhibits HCC growth by regulating glucose and glutamine metabolism and inducing autophagic cell death, thereby highlighting its therapeutic potential for HCC treatment.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • LDHA (Lactate dehydrogenase A) • CCND1 (Cyclin D1) • BAX (BCL2-associated X protein) • DNMT1 (DNA methyltransferase 1) • ATG5 (Autophagy Related 5) • BECN1 (Beclin 1) • PKM (Pyruvate Kinase M1/2) • SLC2A1 (Solute Carrier Family 2 Member 1)
    |
    riluzole
    1m
    Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial (clinicaltrials.gov)
    P2, N=24, Recruiting, University of California, Irvine
    New P2 trial
    |
    riluzole
    4ms
    EGR1 Mediates Riluzole-Induced Apoptosis in Osteosarcoma via the Yap/p73-Bax Signaling Axis. (PubMed, bioRxiv)
    Together, these findings reveal a novel mechanism where Riluzole promotes apoptosis through upregulation of EGR1 , which then cooperates with YAP/p73 to activate Bax expression. These insights establish Riluzole as a promising therapeutic intervention for OS treatment through modulation of the EGR1 /Yap/p73/Bax signaling axis.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • EGR1 (Early Growth Response 1)
    |
    riluzole
    5ms
    A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) (clinicaltrials.gov)
    P1, N=132, Completed, AbbVie | Active, not recruiting --> Completed
    Trial completion • Adverse events
    6ms
    Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma (clinicaltrials.gov)
    P1, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2025 --> Sep 2026
    Trial completion date • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL2L11 (BCL2 Like 11)
    |
    sorafenib • riluzole
    8ms
    Effectiveness and safety of riluzole for the treatment of seizures in individuals with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE). (ACTRN12625000845437)
    P2/3, N=5, Not yet recruiting, University of Melbourne
    New P2/3 trial
    |
    SCN8A (Sodium Voltage-Gated Channel Alpha Subunit 8)
    |
    riluzole
    9ms
    A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients (clinicaltrials.gov)
    P1/2, N=153, Recruiting, PLL TX AUSTRALIA PTY LTD | Not yet recruiting --> Recruiting
    Enrollment open
    9ms
    Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors (clinicaltrials.gov)
    P2, N=18, Completed, Jonsson Comprehensive Cancer Center | Recruiting --> Completed | Trial completion date: Nov 2026 --> Nov 2024 | Trial primary completion date: Nov 2025 --> Nov 2024
    Trial completion • Trial completion date • Trial primary completion date
    9ms
    A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) (clinicaltrials.gov)
    P1, N=132, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed • Adverse events